Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Tividenofusp Alfa

  • Home
  • Tividenofusp Alfa
Breakthrough in Hunter Syndrome: Brain-Penetrant Enzyme Therapy Stabilizes Cognitive Function and Clears Lysosomal Substrates
Posted inNeurology news Pediatrics

Breakthrough in Hunter Syndrome: Brain-Penetrant Enzyme Therapy Stabilizes Cognitive Function and Clears Lysosomal Substrates

Posted by MedXY By MedXY 12/31/2025
A Phase 1-2 study of tividenofusp alfa reveals a 91% reduction in CSF heparan sulfate and stabilized adaptive behavior in children with MPS II, overcoming the blood-brain barrier via transferrin receptor-mediated transport.
Read More
  • Extra-Endocrine Features in Infancy as Early Clues to Multiple Endocrine Neoplasia Type 2B: A Case Series from Bambino Gesù Children’s Hospital
  • Agency-Level Variability in Futility Determinations and Termination of Resuscitation for Pediatric Out-of-Hospital Cardiac Arrest
  • Early Exclusive Enteral Feeding in Preterm Infants: Assessing Safety and Benefits through Meta-Analysis
  • Systemic Therapy for Metastatic Castration-Resistant Prostate Cancer: Key Recommendations from the ASCO Living Guideline (Version 2026.1.4)
  • Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma: Promising Efficacy Across HER2 Expression Levels
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in